FrancophonIA/ELRC3.0 huggingface dataset:
English: By blocking the activity of IL-1 beta, Ilaris may improve these symptoms.
Danish: Ved at blokkere aktiviteten af IL-1 beta kan Ilaris lindre disse symptomer.
English: Treatment with Ilaris may result in dizziness/vertigo or asthenia (see section 4.8).
Danish: Behandling med Ilaris kan give svimmelhed/vertigo eller asteni (se pkt.
English: The apparent volume of distribution per kg (V/F per kg) was 0.14 l/kg.
Danish: Den tilsyneladende fordelingsvolumen pr. kg (V/F pr. kg) var 0,14 l/kg.
English: Transient and asymptomatic cases of elevations of serum transaminases or bilirubin have been reported in clinical trials (see section 4.8).
Danish: Der er rapporteret forbigående og asymptomatiske forhøjelser af transaminaser i serum eller bilirubin i kliniske forsøg (se pkt.
English: If not used immediately after reconstitution, the solution should be kept at 2°C to 8°C and used within 24 hours.
Danish: Hvis den ikke anvendes straks efter rekonstitution, skal opløsningen opbevares ved 2 °C til 8 °C og anvendes inden for 24 timer.
English: The decision whether to breast-feed during canakinumab therapy should therefore only be taken after a thorough benefit-risk evaluation.
Danish: Beslutningen om, hvorvidt kvinden kan amme under behandlingen med canakinumab, skal derfor tages efter grundig vurdering af fordele/risici.
English: Therefore patients should be monitored carefully for signs and symptoms of infections during and after treatment with canakinumab.
Danish: Patienter skal derfor monitoreres omhyggeligt for objektive tegn og symptomer på infektioner under og efter behandling med canakinumab.
English: Resolution of the index disease flare was defined as having a Physician's Global Assessment (PGA) of Disease Activity score < 2 (“minimal or no disease”) and CRP within normal range (≤ 10 mg/l) or reduction ≥ 70% from baseline.
Danish: Ophør af opblussen af indekssygdom blev defineret som havende en PGA (Physician's Global Assessment) sygdomsaktivitetsscore <2 (minimal eller ingen sygdom) og CRP inden for normalområdet (≤10 mg/l) eller reduktion på ≥70 % i forhold til baseline.
English: Drop in level of blood cells which help prevent bleeding (platelets).
Danish: Nedsat antal blodplader, som er med til at forebygge blødning.
English: Injecting Ilaris yourself or injecting a patient with Ilaris If you are a patient with CAPS, TRAPS, HIDS/MKD, FMF or Still's disease (AOSD or SJIA), or a caregiver of a patient with one of these conditions, you may administer Ilaris injections yourself after proper training in the correct injection technique.
Danish: Hvis du giver dig selv indsprøjtning af Ilaris eller giver en patient Ilaris Hvis du er patient med CAPS, TRAPS, HIDS/MKD, FMF eller Stills sygdom (AOSD eller SJIA) eller omsorgsperson for en patient med en af disse sygdomme, kan du give indsprøjtninger med Ilaris efter grundig undervisning i korrekt indsprøjtningsteknik.
English: The following are suitable injection sites: upper thigh, abdomen, upper arm or buttocks.
Danish: Følgende steder er passende injektionssteder: øverste del af låret, abdomen, overarm eller balder.
English: • Cryopyrin-associated periodic syndromes (CAPS),
Danish: • Kryopyrin-associerede periodiske syndromer (CAPS),
English: Then gently turn the vial upside down and back again ten times.
Danish: Vend derpå forsigtigt hætteglasset på hovedet og tilbage igen ti gange.
English: Allow the vial to warm to room temperature before injection.
Danish: Lad hætteglasset opnå stuetemperatur før injektion.
English: After repeated administration of 4 mg/kg every 4 weeks the accumulation ratio of canakinumab was 1.6 fold in SJIA patients.
Danish: Efter gentagen administration af 4 mg/kg hver 4. uge var akkumuleringsratio for canakinumab 1,6 gange hos SJIA-patienter.
English: All up-titrated patients remained at the increased dose of 300 mg (or 4 mg/kg for patients ≤ 40 kg) every 4 weeks.
Danish: Alle optitrerede patienter forblev på den højere dosis på 300 mg (eller 4 mg/kg for patienter ≤40 kg) hver 4. uge.
English: TRAPS, HIDS/MKD and FMF: Adults, adolescents and children aged 2 years and older The recommended starting dose of canakinumab in TRAPS, HIDS/MKD and FMF patients is:
Danish: TRAPS, HIDS/MKD og FMF: Voksne, unge og børn på 2 år og derover Den anbefalede startdosis af canakinumab til patienter med TRAPS, HIDS/MKD og FMF er:
English: What Ilaris is
Danish: Hvad er Ilaris
English: Paediatric patients:
Danish: Pædiatriske patienter
English: • Other infections such as ear infection, skin infection (cellulitis), stomach pain and feeling sick (gastroenteritis) and painful and frequent urination with or without fever (urinary tract infection).
Danish: • Andre infektioner, som fx ørebetændelse, hudinfektion (cellulitis), mavesmerter og kvalme (mavetarmkatar) og smertefuld og hyppig vandladning med eller uden feber (blærebetændelse).
English: At day 15, the median change from baseline in the number of joints with active arthritis and limited range of motion were -67% and -73% for canakinumab (N=43), respectively, compared to a median change of 0% and 0% for placebo (N=41).
Danish: På dag 15 var den mediane ændring fra baseline i antallet af led med aktiv artritis og begrænset bevægelsesinterval henholdsvis -67 % og -73 % for canakinumab (N=43), sammenlignet med en median ændring på 0 % og 0 % for placebo (N=25).
English: CAPS, TRAPS, HIDS/MKD, FMF and SJIA: Ilaris can be used in children aged 2 years and older.
Danish: CAPS, TRAPS, HIDS/MKD, FMF og SJIA: Ilaris kan bruges til børn på 2 år og derover.
English: Study G2306
Danish: Studie G2306
English: Slowly inject the water into the vial containing the Ilaris powder.
Danish: Sprøjt langsomt vandet ind i hætteglasset med Ilaris-pulver.
English: A gouty arthritis attack is caused by urate (monosodium urate monohydrate) crystals in the joint and surrounding tissue, which trigger resident macrophages to produce IL-1 beta via the “NALP3 inflammasome” complex.
Danish: Et anfald af urinsyregigt er forårsaget af urat- (mononatirum-urat-monohydrat) krystaller i leddet og det omgivende væv, som aktiverer residente makrofager til at producere IL-1 beta via ”NALP3inflammasom” komplekset.
English: In study G2305, the Childhood Health Assessment Questionnaire Least Squares means improvement was 0.69 for canakinumab vs placebo representing 3.6 times the minimal clinically important difference of 0.19 (p=0.0002).
Danish: I studie G2305 var forbedringen i henhold til Childhood Health Assessment's spørgeskema beregnet ved mindste kvadraters metode 0,69 for canakinumab versus placebo, hvilket er 3,6 gange den mindste klinisk vigtige forskel på 0,19 (p=0,0002).
English: In Part II of the study, patients treated with canakinumab who had persistent disease activity received an additional dose of 150 mg (or 2 mg/kg for patients ≤ 40 kg) within the first month.
Danish: I del II af studiet fik patienter, som blev behandlet med canakinumab og havde vedvarende sygdomsaktivitet, endnu en dosis på 150 mg (eller 2 mg/kg for patienter ≤40 kg) inden for den første måned.
English: Dispose of the needle and syringe in the sharps container without recapping or removing the needle.
Danish: Smid kanylen og sprøjten i kanyleboksen uden at sætte hætte på eller fjerne kanylen.
English: Apparent clearance (CL/F) in the TRAPS, HIDS/MKD and FMF population at body weight of 55 kg (0.14 l/d) was comparable to CAPS population at body weight of 70 kg (0.17 l/d).
Danish: Den tilsyneladende clearance (CL/F) hos TRAPS-, HIDS/MKD- og FMF-populationen ved en legemsvægt på 55 kg (0,14 l/dag) var sammenlignelig med CAPS-populationen ved en legemsvægt på 70 kg (0,17 l/dag).
English: Tip the vial to ensure that the required amount of solution can be drawn into the syringe.
Danish: Vip hætteglasset for at sikre, at den nødvendige mængde opløsning kan trækkes ind i sprøjten.
English: Mean values for Cmax and AUCinf after a single subcutaneous dose of 150 mg in a typical adult CAPS patient (70 kg) were 15.9 µg/ml and 708 µg*d/ml.
Danish: Gennemsnitlige værdier for Cmax og AUCinf efter en enkel subkutan dosis på 150 mg hos en typisk voksen CAPS-patient (70 kg) var 15,9 µg/ml og 708 µg*dag/ml.
English: p=0.2798 Risk reduction of subsequent gouty arthritis attacks as measured by time to first new flare (24 weeks)
Danish: Risikoreduktion for efterfølgende urinsyregigt-anfald målt som tid til først nye udbrud (24 uger)
English: Following canakinumab treatment, the inflammatory markers CRP or SAA and signs of acute inflammation (e.g. pain, swelling, redness) in the affected joint subside rapidly.
Danish: Ved behandling med canakinumab aftager inflammationsmarkørerne CRP eller SAA og symptomerne på akut inflammation (fx smerte, hævelse, rødme) i de berørte led hurtigt.
English: CAPS in children 2-< 4 years of age or children  4 years of age  7.5 kg and < 15 kg
Danish: CAPS hos børn mellem 2-<4 år eller børn ≥4 år ≥7,5 kg og <15 kg
English: Do not touch the needles or the top of the vial.
Danish: Rør ikke ved kanylen eller toppen af hætteglasset.
English: In case of overdose, it is recommended for the patient to be monitored for any signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted immediately.
Danish: I tilfælde af overdosering anbefales det at monitorere patienten for objektive tegn og symptomer på bivirkninger.
English: Phase III trial, pivotal placebo-controlled withdrawal period (Part II) Canakinumab N=15 n(%)
Danish: Fase III-studiets pivotale placebokontrollerede seponeringsperiode (del II) Canakinumab N=15 n(%)
English: TRAPS, HIDS/MKD and FMF patients with body weight > 40 kg
Danish: TRAPS-, HIDS/MKD- og FMF-patienter med legemsvægt >40 kg
English: Ilaris is injected every 4 weeks as a single dose.
Danish: Ilaris indsprøjtes hver 4. uge som en enkelt dosis.
English: Mild and transient Grade 1 reduction in platelets occurred in 15.9% of patients without any associated bleeding adverse events.
Danish: En let og forbigående reduktion i trombocyttal af grad 1 uden uønsket relateret blødningstilfælde forekom hos 15,9 % af patienterne.
English: Take off the protective cap from the Ilaris vial.
Danish: Fjern beskyttelseshætten fra Ilaris hætteglasset.
English: Packs containing 1 vial or multipacks containing 4 (4x1) vials.
Danish: Pakninger med 1 hætteglas eller multipakninger med 4 (4x1) hætteglas.
English: When stratified by weight, a lower (30-40%) median of exposure for Cmin,ss (11.4 vs 19 µg/ml) and AUCss (594 vs 880 µg*d/ml) for the lower bodyweight category (≤ 40 kg) vs the higher bodyweight category (> 40 kg) was observed.
Danish: Ved stratificering efter vægt sås en lavere (30-40 %) middeleksponering for Cmin,ss (11,4 mod 19 μg/ml) og AUCss (594 mod 880 μg*dag/ml) i den lave vægtkategori (≤ 40 kg) versus den høje vægtkategori (> 40 kg).
English: Overall, the efficacy, safety and tolerability profile of canakinumab in elderly patients ≥ 65 years of age was comparable to patients < 65 years of age.
Danish: Samlet set er canakinumab's virknings-, sikkerheds- og tolerabilitetsprofil sammenlignelig hos ældre patienter ≥65 år og hos patienter <65 år.
English: If you have not responded well enough to the treatment after 7 days, your doctor may give you another dose of 150 mg or 2 mg/kg.
Danish: Hvis du ikke har reageret godt nok på behandlingen efter 7 dage, vil din læge måske give dig endnu en dosis på 150 mg eller 2 mg/kg.
English: Phase III trial, pivotal, randomised placebo-controlled treatment period (Part II) Canakinumab n/N (%)
Danish: Fase III-studiets pivotale, randomiserede, placebokontrollerede behandlingsperiode (del II) Canakinumab n/N (%)
English: Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate (see section 5.1).
Danish: Ilaris er indiceret til symptomatisk behandling af voksne patienter med hyppige anfald af urinsyregigt (mindst 3 anfald inden for 12 måneder), hvor non-steroid antiinflammatorisk medicin (NSAID) og colchicin er kontraindiceret, ikke tåles, eller ikke giver tilstrækkeligt respons, og hvor gentagne behandlinger med kortikosteroider ikke er egnede (se pkt.
English: An additional pharmacokinetics analysis showed that the pharmacokinetics of canakinumab in 6 paediatric CAPS patients under the age of 2 years were similar to the pharmacokinetics in paediatric patients 2-4 years of age.
Danish: En yderligere farmakokinetisk analyse viste, at canakinumabs farmakokinitik hos 6 pædiatriske CAPS-patienter under 2 år var sammenlignelig med farmakokinetikken hos pædiatriske patienter i alderen 2-4 år.
English: Decreases in absolute neutrophil counts (ANC) to less than 1 x 10
Danish: Fald i absolut neutrofiltal (ANC) til <1 x 10
English: Allergic reactions with rash and itching and possibly also hives, difficulty breathing or swallowing, dizziness, unusual awareness of your heart beat (palpitations) or low blood pressure.
Danish: Allergiske reaktioner med udslæt og kløe og muligvis også nældefeber, besvær med vejrtrækningen eller med at synke, svimmelhed, hjertebanken eller lavt blodtryk.
English: Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as canakinumab, is introduced.
Danish: CYP-ekspressionen kan derfor genoprettes ved introduktion af en potent cytokin-hæmmende behandling, som fx canakinumab.
English: Open the wrappers containing the syringe and the transfer needle (the 50 mm needle) and attach the needle to the syringe.
Danish: Åbn pakningerne, der indeholder sprøjten og overførselskanylen (50 mm nålen), og sæt kanylen på sprøjten.
English: • Severe forms of familial cold auto-inflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.
Danish: • Alvorlige former for familiært kulde autoinflammatorisk syndrom (FCAS)/familiært kulde-urticaria (FCU), som viser sig ved tegn og symptomer ud over nældefeber fremkaldt af kulde.
English: TRAPS, HIDS/MKD and FMF patients with body weight  7.5 kg and ≤ 40 kg
Danish: TRAPS-, HIDS/MKD- og FMF-patienter med legemsvægt 7,5 kg og ≤40 kg
English: Study G2306 was an open-label study to assess maintenance of treatment response with canakinumab dose reduction (2 mg/kg every 4 weeks) or dose interval prolongation (4 mg/kg every 8 weeks) in SJIA patients who were receiving canakinumab 4 mg/kg every 4 weeks.
Danish: Studie G2306 var et åbent studie som skulle vurdere vedligeholdelsen af behandlingsresponset med dosisreduktion af canakinumab (2 mg/kg hver 4. uge) eller forlængelse af dosisinterval (4 mg/kg hver 8. uge) hos SJIA-patienter, som fik canakinumab 4 mg/kg hver 4. uge.
English: Canakinumab should not be administered during an active infection.
Danish: Behandling af urinsyregigt Canakinumab bør ikke administreres under en aktiv infektion.
English: Predicted steady-state exposure values (Cmin,ss, Cmax,ss, AUC,ss,8w) after 150 mg subcutaneous administration (or 2 mg/kg, respectively) every 8 weeks were slightly higher in the weight category 40-70 kg (6.6 µg/ml, 24.3 µg/ml, 767 µg*d/ml) compared to the weight categories < 40 kg (4.0 µg/ml, 19.9 µg/ml, 566 µg*d/ml) and > 70 kg (4.6 µg/ml, 17.8 µg/ml, 545 µg*d/ml).
Danish: Forventede steady state eksponeringsværdier (Cmin,ss, Cmax,ss, AUC,ss,8w) efter 150 mg subkutan administration (eller 2 mg/kg respektivt) hver 8. uge var lidt højere i vægtkategorien 40-70 kg (6,6 µg/ml; 24,3 µg/ml; 767 µg∙dag/ml) sammenlignet med vægtkategorierne <40 kg (4,0 µg/ml; 19,9 µg/ml; 566 µg∙dag/ml) og >70 kg (4,6 µg/ml; 17,8 µg/ml; 545 µg∙dag/ml).
English: Tumour necrosis factor receptor associated periodic syndrome (TRAPS) Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).
Danish: Tumornekrosefaktor-receptor-associeret periodisk syndrom (TRAPS) Ilaris er indiceret til behandling af tumornekrosefaktor (TNF)-receptor-associeret periodisk syndrom (TRAPS).
English: Study G2301
Danish: Studie G2301
English: A 56-week, open-label study was conducted to assess the efficacy, safety and tolerability of canakinumab in paediatric CAPS patients ≤ 4 years of age.
Danish: Et 56-ugers åbent studie blev udført for at undersøge canakinumab virkning, sikkerhed og tolerabilitet hos CAPS-patienter ≤ 4 år.
English: Additional dose of 150 mg can be considered
Danish: En yderligere dosis på 150 mg kan overvejes
English: A murine antimurine IL-1 beta antibody had no undesirable effects on fertility in male or female mice (see section 5.3).
Danish: Et murint anti-murin IL-1 beta-antistof havde ingen uønskede virkninger på fertiliteten hos han- og hunmus (se pkt.
English: Primary endpoint (disease flare) - Proportion of patients who had index disease flare resolution at day 15 and did not experience a new flare during the remainder of the 16-week treatment period FMF
Danish: Primært endepunkt (sygdomsopblussen) - Andel af patienter, som havde ophør af opblussen af indekssygdom ved dag 15 og ikke havde en ny opblussen i resten af behandlingsperioden på 16 uger FMF
English: The primary efficacy endpoint of the randomised treatment period (Part II) was the proportion of responders within each cohort who had resolution of their index disease flare at Day 15 and did not experience a new flare during the remainder of the 16-week treatment period (defined as complete response).
Danish: Det primære effektendepunkt i den randomiserede behandlingsperiode (del II) var andelen af respondenter i hver kohorte, som havde ophør af opblussen af deres indekssygdom ved dag 15 og ikke havde en ny opblussen i resten af behandlingsperioden på 16 uger (defineret som komplet respons).
English: Insert the needle all the way into the vial until it reaches the bottom edge.
Danish: Før kanylen hele vejen ned i hætteglasset, indtil den når bunden.
English: The peak serum canakinumab concentration (Cmax) occurred approximately 7 days following single subcutaneous administration of 150 mg in adult CAPS patients.
Danish: Den maksimale koncentration af canakinumab i serum (Cmax) indtraf ca. 7 dage efter enkelt subkutan administration af 150 mg hos voksne CAPS-patienter.
English: MedDRA System Organ Class
Danish: MedDRAOrganklassesystem
English: There were 80 paediatric CAPS patients (2-17 years of age) who received canakinumab in the interventional studies.
Danish: 80 pædiatriske CAPS-patienter (2-17 år) blev behandlet med canakinumab i interventionsstudierne.
English: Pain in the back or muscles.
Danish: Rygsmerter eller muskelsmerter.
English: Adult-onset Still's disease and systemic juvenile idiopathic arthritis are severe autoinflammatory diseases, driven by innate immunity by means of pro-inflammatory cytokines, a key one being IL-1beta.
Danish: Stills sygdom hos voksne og systemisk juvenil idiopatisk artritis er alvorlige autoinflammatoriske sygdomme, der skyldes den medfødte immunitet og udløses af pro-inflammatoriske cytokiner, hvor IL-1-beta er en væsentlig faktor.
English: 9/l) and transient decreases in platelet counts were observed at a higher incidence (12.7%) with canakinumab in the active-controlled clinical studies versus the comparator (7.7%) in gouty arthritis patients.
Danish: 9/l) og forbigående fald i antal blodplader blev observeret med en hyppigere forekomst med canakinumab (12,7 %) versus komparator (7,7 %) i de aktiv-kontrollerede kliniske studier hos urinsyregigt-patienter.
English: Read all the way through these instructions before injecting.
Danish: Læs hele denne vejledning igennem, inden du tager indsprøjtningen.
English: The solution should be clear to opalescent and free of visible particles.
Danish: Opløsningen skal være klar til opaliserende og fri for synlige partikler.
English: These include shivering, chills, malaise, loss of appetite, body aches, typically in connection with a sudden onset of illness, sore throat or mouth ulcers, cough, phlegm, chest pain, difficulty breathing, ear pain, prolonged headache or localised redness, warmth or swelling of your skin or inflammation of connective tissue (cellulitis).
Danish: Dette omfatter kulderystelser, forkølelse, utilpashed, appetitløshed, smerter i kroppen, typisk i forbindelse med pludselig sygdom, ondt i halsen eller mundsår, hoste, slim, brystsmerter, vejrtrækningsproblemer, øresmerter, langvarig hovedpine eller lokal rødme, varme eller hævelse i huden eller betændelse i bindevæv (cellulitis).
English: Study G2305 was a randomised, double-blind, placebo-controlled, 4-week study assessing the shortterm efficacy of canakinumab in 84 patients randomised to receive a single dose of 4 mg/kg (up to 300 mg) canakinumab or placebo.
Danish: Studie G2305 var et randomiseret, dobbelblindet, placebokontrolleret studie på 4 uger, der vurderede korttidseffekten af canakinumab hos 84 patienter randomiseret til at få en enkelt dosis på 4 mg/kg (op til 300 mg) canakinumab eller placebo.
English: Make sure 1.0 ml of water is in the syringe, then take the needle out of the vial.
Danish: Kontrollér, at der er 1,0 ml vand i sprøjten, og træk så kanylen ud af hætteglasset.
English: Immediately proceed to administering the injection.
Danish: Fortsæt straks med indsprøjtningen.
English: Concomitant use of canakinumab with tumour necrosis factor (TNF) inhibitors is not recommended because this may increase the risk of serious infections (see section 4.5).
Danish: Brug af canakinumab samtidig med tumornekrosefaktor (TNF)-hæmmere frarådes, da dette kan øge risikoen for alvorlige infektioner (se pkt.
English: Clean the rubber stopper of the vial containing the Ilaris solution with a new alcohol swab.
Danish: Rens gummiproppen fra hætteglasset, der indeholder Ilaris-opløsningen, med en ny spritserviet.
English: Canakinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators.
Danish: Canakinumab binder sig med høj affinitet specifikt til human IL-1 beta og neutraliserer human IL-1 betas biologiske aktivitet ved at blokere dets interaktion med IL-1-receptorer.
English: The safety and efficacy of Ilaris in CAPS, TRAPS, HIDS/MKD and FMF patients under 2 years of age have not been established.
Danish: Ilaris' sikkerhed og virkning hos CAPS-, TRAPS-, HIDS/MKD- og FMF-patienter under 2 år er ikke klarlagt.
English: Peak concentrations of canakinumab occurred between 2 to 7 days (Tmax) following single subcutaneous administration of canakinumab 150 mg or 2 mg/kg in paediatric patients 4 years of age and older.
Danish: Maksimal koncentration af canakinumab indtraf 2 til 7 dage (Tmax) efter en enkelt subkutan administration af canakinumab 150 mg eller 2 mg/kg hos pædiatriske patienter i alderen 4 år og derover.
English: TRAPS n=number of responders; N=number of evaluable patients * indicates statistical significance (one-sided) at the 0.025 level based on Fisher exact test **Indicates statistical significance (one-sided) at the 0.025 level based on the logistic regression model with treatment group and baseline PGA, CRP or SAA respectively, as explanatory variables for each cohort
Danish: *Angiver statistisk signifikans (1-sidet) ved 0,025-niveauet baseret på Fisher's exact test. **Angiver statistisk signifikans (1-sidet) ved 0,025-niveauet baseret på den logistiske regressionsmodel med henholdsvis behandlingsgruppe og baseline-PGA, -CRP eller -SAA som forklarende variabler for hver kohorte.
English: Use of canakinumab with TNF inhibitors is not recommended because this may increase the risk of serious infections.
Danish: Samtidig brug af canakinumab og TNF-hæmmere frarådes, da dette kan øge risikoen for alvorlige infektioner.
English: Ilaris is used in adults to treat the symptoms of frequent gouty arthritis attacks if other treatments have not worked well enough.
Danish: Ilaris anvendes til behandling af symptomer ved hyppige anfald af urinsyregigt hos voksne, som ikke har haft tilstrækkelig virkning af anden behandling.